This peer-reviewed article explores psilocybin as a therapy for depression in cancer patients, a condition often resistant to standard antidepressants. Evidence highlights psilocybin’s ability to reduce emotional distress and improve quality of life, while legal barriers remain a major hurdle to broader clinical use. The paper stresses the need for updated regulations so that safe, supervised psilocybin therapy can be integrated into oncology care.